Vesalius holds final close on €120m

The vehicle was launched in March 2017 and held a first close on €65m in May 2017, and an interim close on €110m in January this year. It had a target of €150m.

The fund's predecessor, Vesalius Biocapital II, held a final close on €80m against a €100m target in 2013.

Investors
The fund attracted commitments from investors in Europe, the Americas, the Middle East and North Africa. The European Investment Fund made a €30m commitment to the vehicle.

Investments
The fund has completed three investments to date: Portuguese medical equipment business Sword Health in April 2018;  Finnish pharmaceutical company Forendo Pharma in September 2018; and German medical technology firm Mecuris in January this year.

It will continue investing in later-stage European life-sciences companies in drug development, medtech, diagnostics and digital health with the goal of building a portfolio of 10-15 companies.

People
Versalius Biocapital – Christian Schneider, Stéphane Verdood (managing partners).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Healthcare
• Venture
• Luxembourg